(MT Newswires) -- Pfizer Inc. (PFE) is purchasing cancer-drug maker Seagen Inc. (SGEN) for an enterprise value of $43 billion, using the biggest deal of the year to set its course out of the pandemic and back into mainstream pharma. Pfizer CEO Dr. Albert Bourla speaks to David Westin.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
28.8 USD | -2.69% | -0.55% | -0.10% |
06:32pm | Global markets live: Anglo American, Nvidia, Apple, Amazon, Tesla, Walt Disney... | |
03:34pm | Pfizer: initiative against antibiotic resistance in Malawi | CF |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.10% | 168B | |
+38.16% | 723B | |
+34.28% | 595B | |
-4.51% | 369B | |
+20.01% | 332B | |
+2.55% | 282B | |
+17.02% | 244B | |
+9.31% | 208B | |
-5.07% | 205B | |
+6.61% | 166B |
- Stock Market
- Equities
- PFE Stock
- News Pfizer, Inc.
- INTERVIEW - Pfizer CEO Albert Bourla on the Seagen deal, growth and regulatory risks